Immunotherapies for Prostate Cancer

Publication
Article
Special ReportsImmunotherapy (Issue 4)
Volume 4
Issue 1

William K. Oh, MD, discusses immunotherapies for the treatment of patients with prostate cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses immunotherapies for the treatment of patients with prostate cancer.

<<<

Back to the Immunotherapy Special Report

Articles in this issue
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Question
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Question
Programs Prepare for Immuno-Oncology in Clinical Setting
Programs Prepare for Immuno-Oncology in Clinical Setting
Right Patient for Immunotherapy in NSCLC Explored
Right Patient for Immunotherapy in NSCLC Explored
Weight May Affect Toxicity of Immunotherapies
Weight May Affect Toxicity of Immunotherapies
Adverse Events Associated With Immunotherapy in Lung Cancer
Adverse Events Associated With Immunotherapy in Lung Cancer
Immunotherapy Potential Option in Mesothelioma Treatment
Immunotherapy Potential Option in Mesothelioma Treatment
Potential Immunotherapies for Head and Neck Cancers
Potential Immunotherapies for Head and Neck Cancers
Immunotherapies for Prostate Cancer
Immunotherapies for Prostate Cancer
Recent Videos
Related Content
OST-HER2 Extends 12-Month EFS in Osteosarcoma With Lung Metastases

OST-HER2 Extends 12-Month EFS in Osteosarcoma With Lung Metastases

Jordyn Sava
January 20th 2025
Article

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung metastases.

Read More

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen

Radiotherapy and Abiraterone Improve Outcomes in Low-Volume mCSPC

Radiotherapy and Abiraterone Improve Outcomes in Low-Volume mCSPC

Jordyn Sava
January 17th 2025
Article

In an interview, Cedric Pobel, MD, further discussed the PEACE-1 trial and its findings.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer

Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer

Jonah Feldman
January 17th 2025
Article

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.

Read More

What Is Dark Zone Lymphoma, and Is It Clinically Relevant?

What Is Dark Zone Lymphoma, and Is It Clinically Relevant?

Brett Collinge, PhD candidate;David W. Scott, MBChB, PhD
January 16th 2025
Article

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.

Read More